Mayne Pharma Resolves Patent Litigation with Sun Pharma
Key points
- Settlement resolves US litigation concerning IMVEXXY® patents
- Agreed market entry date for generic IMVEXXY® set for 21 October 2032
- Settlement highlights validity of IMVEXXY® patent portfolio
- Mayne Pharma continues to defend its IP portfolio
Full summary
Mayne Pharma Group Limited (ASX: MYX) has announced the resolution of US patent litigation with Sun Pharma concerning IMVEXXY® (estradiol vaginal inserts). The settlement resolves the Paragraph IV litigation and provides a pathway for Sun Pharma's generic product entry on 21 October 2032. The settlement does not involve any financial payment and underscores the validity and enforceability of Mayne Pharma's IMVEXXY® patent portfolio. Mayne Pharma will continue to actively manage and defend its intellectual property estate, with the last expiring patent set for February 2034.
Summary generated by a large language model. Please interpret with care.